• Alphamab Oncology filed a next-day disclosure return showing a repurchase of 118,000 ordinary shares on Sept. 9.
• Shares were bought on the Exchange at HKD 8.27–HKD 8.45 each; aggregate consideration was HKD 989,670.
• Repurchased shares were held as treasury shares; cancelled shares totaled 0.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260909-12326484), on September 09, 2026, and is solely responsible for the information contained therein.